Houlihan Lokey reports its fiscal Q1 results today after market close, with options positioning shifting notably more defensive even as the stock's recent rally keeps the broader setup constructive.
The clearest shift heading into the print is in options. The put/call ratio has climbed to 0.30, more than one standard deviation above its 20-day average of 0.20 — a meaningful move for a name where puts have consistently lagged calls over the past year. That's a modest but genuine tilt toward downside protection, arriving just as the stock has added 3% on the week and almost 5% on the month to close at $145.47. The short-interest picture does nothing to amplify the caution: short interest is only 3.3% of the free float, down 2% week-on-week, and borrow availability is extraordinarily loose at roughly 6,664% — meaning there are far more shares available to lend than there are positions already short. Borrowing costs are negligible at 0.40%. Nothing in the lending market signals meaningful bearish conviction.
The analyst debate is genuinely two-sided. Bulls point to a $169.75 consensus price target that implies roughly 17% upside from current levels, and Morgan Stanley maintains an Overweight rating — though it trimmed its target to $187 from $193 earlier this month. Keefe, Bruyette & Woods similarly kept its Outperform while cutting to $160. The pattern across the Street is consistent: firms like the story on a 12-month view but have been taking near-term targets lower through 2026, partly reflecting HLI's 19.5% year-to-date underperformance against the broader market. Goldman Sachs, which carries a Buy, had already moved its target down from $210 in April. The bear case centers on that trailing momentum — forward EPS estimates rank only in the 16th percentile on 30-day momentum and 18th on 90-day — alongside a P/E near 16x that leaves limited buffer if volumes disappoint. Bulls counter that the restructuring franchise provides a durable pipeline regardless of M&A cycles, and that the forward EPS growth trajectory remains strong in absolute terms.
Among advisory peers, HLI's week-on-week move of roughly 4% puts it broadly in line: PJT Partners added 3.8% and Perella Weinberg about 3%, while Evercore was flat and Lazard dipped nearly 2%. Insider activity from May is worth noting in context — multiple senior executives including the CEO sold shares at around $150, just above current prices, which narrows the gap between insider exit levels and today's price. The net 90-day insider position is a meaningful $8.6 million in net sales, a signal that management was not adding exposure at these levels.
The print will test whether Houlihan Lokey's restructuring and financial advisory fee volumes justify the market's patient recovery thesis — or whether the Street's steady stream of downward target revisions reflects a more fundamental reset in near-term earnings power.
See the live data behind this article on ORTEX.
Open HLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
